GlobalFoundries Inc. Ordinary Shares vs Novo Nordisk A/S — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.24 (market cap $27.51B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6× GlobalFoundries Inc. Ordinary Shares's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Novo Nordisk A/S for 116 Days on average.
| GFS | NVO | |
|---|---|---|
Market Cap | $27.51B | $165.31B |
Volume | 10,416,572 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $89.96 | $63.98 |
52-Week Low | $32.24 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $26.80B | $179.56B |
Dividend Yield | 0.97% | 4.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →